Orthovita, Inc.
Orthovita develops and sells materials for physicians to use as bone substitutes in reconstruction and replacement procedures. The company's products are designed to mimic natural bone characteristics and harden quicker than other available products. Orthovita's VITOSS product line, used for the repair of spinal and pelvic bone defects, accounts for about 60% of the company's sales. Its CORTOSS bone augmentation material -- expected to eventually become Orthovita's lead product -- received North American marketing approval from the FDA in 2009. Orthovita company already sells CORTOSS, which is used to repair vertebral compression fractures, in the EU and Australia.